236 related articles for article (PubMed ID: 27993682)
21. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
22. Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors.
Melick CH; Jewell JL
Biochem J; 2020 May; 477(10):1847-1863. PubMed ID: 32347294
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
24. PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester.
Ni Y; Wang L; Zhang J; Pang Z; Liu Q; Du J
Int J Biochem Cell Biol; 2015 Mar; 60():34-42. PubMed ID: 25578563
[TBL] [Abstract][Full Text] [Related]
25. Ghrelin-induced food intake and adiposity depend on central mTORC1/S6K1 signaling.
Stevanovic D; Trajkovic V; Müller-Lühlhoff S; Brandt E; Abplanalp W; Bumke-Vogt C; Liehl B; Wiedmer P; Janjetovic K; Starcevic V; Pfeiffer AF; Al-Hasani H; Tschöp MH; Castañeda TR
Mol Cell Endocrinol; 2013 Dec; 381(1-2):280-90. PubMed ID: 23994018
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.
Sokolosky M; Chappell WH; Stadelman K; Abrams SL; Davis NM; Steelman LS; McCubrey JA
Cell Cycle; 2014; 13(5):820-33. PubMed ID: 24407515
[TBL] [Abstract][Full Text] [Related]
27. Fisetin regulates obesity by targeting mTORC1 signaling.
Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
[TBL] [Abstract][Full Text] [Related]
28. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
Acevedo-Gadea C; Hatzis C; Chung G; Fishbach N; Lezon-Geyda K; Zelterman D; DiGiovanna MP; Harris L; Abu-Khalaf MM
Breast Cancer Res Treat; 2015 Feb; 150(1):157-67. PubMed ID: 25687356
[TBL] [Abstract][Full Text] [Related]
29. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation.
Alayev A; Salamon RS; Berger SM; Schwartz NS; Cuesta R; Snyder RB; Holz MK
Oncogene; 2016 Jul; 35(27):3535-43. PubMed ID: 26522726
[TBL] [Abstract][Full Text] [Related]
30. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
Karlsson E; Magić I; Bostner J; Dyrager C; Lysholm F; Hallbeck AL; Stål O; Lundström P
PLoS One; 2015; 10(12):e0145013. PubMed ID: 26698305
[TBL] [Abstract][Full Text] [Related]
31. Direct imaging of the recruitment and phosphorylation of S6K1 in the mTORC1 pathway in living cells.
Ahmed AR; Owens RJ; Stubbs CD; Parker AW; Hitchman R; Yadav RB; Dumoux M; Hawes C; Botchway SW
Sci Rep; 2019 Mar; 9(1):3408. PubMed ID: 30833605
[TBL] [Abstract][Full Text] [Related]
32. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
[TBL] [Abstract][Full Text] [Related]
33. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
34. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1).
Pearce LR; Alton GR; Richter DT; Kath JC; Lingardo L; Chapman J; Hwang C; Alessi DR
Biochem J; 2010 Oct; 431(2):245-55. PubMed ID: 20704563
[TBL] [Abstract][Full Text] [Related]
35. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.
Veilleux A; Houde VP; Bellmann K; Marette A
Mol Endocrinol; 2010 Apr; 24(4):766-78. PubMed ID: 20203102
[TBL] [Abstract][Full Text] [Related]
36. Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.
Gu X; Yu JJ; Ilter D; Blenis N; Henske EP; Blenis J
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14960-5. PubMed ID: 23983265
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylated S6 kinase-1: a breast cancer marker predicting resistance to neoadjuvant chemotherapy.
Kim EK; Kim JH; Kim HA; Seol H; Seong MK; Lee JY; Byeon J; Sohn YJ; Koh JS; Park IC; Noh WC
Anticancer Res; 2013 Sep; 33(9):4073-9. PubMed ID: 24023352
[TBL] [Abstract][Full Text] [Related]
39. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.
Noh WC; Kim YH; Kim MS; Koh JS; Kim HA; Moon NM; Paik NS
Breast Cancer Res Treat; 2008 Aug; 110(3):477-83. PubMed ID: 17805960
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer.
Kim EK; Kim HA; Koh JS; Kim MS; Kim KI; Lee JI; Moon NM; Ko E; Noh WC
Breast Cancer Res Treat; 2011 Feb; 126(1):93-9. PubMed ID: 21184268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
